The specific HDAC targets regulated by EWSR1-FLI1 activity provide advantages to EWS tumor cells, and blockade of this regulation via HDAC inhibition could specifically sensitize EWS cells to BML-281 treatment. This evidence concerns the gene EWSR1 and neoplasm.